Table 1.
Table of clinical variables and their distribution in the complete set of 178 patients, the subset of 127 patients and in the CRC tumour microbial subtypes, respectively. (For categorical variable, Fisher exact test was performed and for continuous data, Kruskal-Wallis test was used.).
| Clinical Variables | Data Subset Comparison | Tumour Microbiome Subtypes | |||||
|---|---|---|---|---|---|---|---|
| All Tumours (n = 178) | Triplets (n = 127) | p-Value | TMS1 (n = 46) | TMS2 (n = 55) | TMS3 (n = 77) | p-Value | |
| age at diagnosis | Mean (SD) | Mean (SD) | 0.804 | Mean (SD) | Mean (SD) | Mean (SD) | 0.887 |
| 66.92 (10.66) | 66.61 (10.61) | - | 66.89 (9.88) | 67.47 (11.39) | 66.55 (10.69) | - | |
| gender | n (%) | n (%) | 1 | n (%) | n (%) | n (%) | 0.729 |
| male | 99 (55.6) | 70 (55.1) | - | 25 (54.3) | 33 (60.0) | 41 (53.2) | - |
| female | 79 (44.4) | 57 (44.9) | - | 21 (45.7) | 22 (40.0) | 36 (46.8) | - |
| tumour localisation | n (%) | n (%) | 0.597 | n (%) | n (%) | n (%) | <0.001 |
| right | 64 (36.0) | 48 (37.8) | - | 28 (60.9) | 11 (20.0) | 25 (32.5) | - |
| transverse | 19 (10.7) | 13 (10.2) | - | 6 (13.0) | 5 (9.1) | 8 (10.4) | - |
| left | 44 (24.7) | 36 (28.3) | - | 4 (8.7) | 17 (30.9) | 23 (29.9) | - |
| rectosigmoideum | 32 (18.0) | 23 (18.1) | - | 6 (13.0) | 10 (18.2) | 16 (20.8) | - |
| rectum | 19 (10.7) | 7 (5.5) | - | 2 (4.3) | 12 (21.8) | 5 (6.5) | - |
| grade | n (%) | n (%) | 0.998 | n (%) | n (%) | n (%) | <0.001 |
| NA, in situ | 7 (3.9) | 5 (3.9) | - | 0 (0.0) | 3 (5.5) | 4 (5.2) | - |
| 1 | 18 (10.1) | 12 (9.4) | - | 1 (2.2) | 5 (9.1) | 12 (15.6) | - |
| 2 | 102 (57.3) | 73 (57.5) | - | 18 (39.1) | 37 (67.3) | 47 (61.0) | - |
| 3 | 51 (28.7) | 37 (29.1) | - | 27 (58.7) | 10 (18.2) | 14 (18.2) | - |
| AJCC stage | n (%) | n (%) | 0.968 | n (%) | n (%) | n (%) | 0.136 |
| 0 | 8 (4.5) | 6 (4.7) | - | 0 (0.0) | 3 (5.5) | 5 (6.5) | - |
| I | 31 (17.4) | 26 (20.5) | - | 2 (4.3) | 12 (21.8) | 17 (22.1) | - |
| II | 66 (37.1) | 45 (35.4) | - | 21 (45.7) | 19 (34.5) | 26 (33.8) | - |
| III | 48 (27.0) | 34 (26.8) | - | 16 (34.8) | 12 (21.8) | 20 (26.0) | - |
| IV | 25 (14.0) | 16 (12.6) | - | 7 (15.2) | 9 (16.4) | 9 (11.7) | - |
| tumour pathologic stage | n (%) | n (%) | 0.979 | n (%) | n (%) | n (%) | 0.007 |
| pTis | 8 (4.5) | 6 (4.7) | - | 0 (0.0) | 3 (5.5) | 5 (6.5) | - |
| pT1 | 11 (6.2) | 10 (7.9) | - | 0 (0.0) | 5 (9.1) | 6 (7.8) | - |
| pT2 | 32 (18.0) | 24 (18.9) | - | 2 (4.3) | 12 (21.8) | 18 (23.4) | - |
| pT3 | 115 (64.6) | 79 (62.2) | - | 42 (91.3) | 30 (54.5) | 43 (55.8) | - |
| pT4 | 12 (6.7) | 8 (6.3) | - | 2 (4.3) | 5 (9.1) | 5 (6.5) | - |
| regional lymph nodes pathologic stage | n (%) | n (%) | 0.618 | n (%) | n (%) | n (%) | 0.041 |
| pN0 | 109 (61.2) | 79 (62.2) | - | 23 (50.0) | 36 (65.5) | 50 (64.9) | - |
| pN1 | 46 (25.8) | 36 (28.3) | - | 13 (28.3) | 10 (18.2) | 23 (29.9) | - |
| pN2 | 23 (12.9) | 12 (9.4) | - | 10 (21.7) | 9 (16.4) | 4 (5.2) | - |
| synchronous distant metastasis | n (%) | n (%) | 0.846 | n (%) | n (%) | n (%) | 0.722 |
| M0 | 153 (86.0) | 111 (87.4) | - | 39 (84.8) | 46 (83.6) | 68 (88.3) | - |
| M1 | 25 (14.0) | 16 (12.6) | - | 7 (15.2) | 9 (16.4) | 9 (11.7) | - |
| MSI/MSS | n (%) | n (%) | 1 | n (%) | n (%) | n (%) | <0.001 |
| MSI | 27 (15.2) | 19 (15.0) | - | 16 (34.8) | 4 (7.3) | 7 (9.1) | - |
| MSS | 110 (61.8) | 81 (63.8) | - | 22 (47.8) | 37 (67.3) | 51 (66.2) | - |
| NA | 41 (23.0) | 27 (21.2) | - | 8 (17.4) | 14 (25.4) | 19 (24.7) | - |
| BRAF | n (%) | n (%) | 1 | n (%) | n (%) | n (%) | 0.022 |
| BRAF wt | 77 (43.3) | 53 (41.7) | - | 17 (37.0) | 27 (49.1) | 33 (42.9) | - |
| BRAF mut | 12 (6.7) | 9 (7.1) | - | 7 (15.2) | 1 (1.8) | 4 (5.2) | - |
| NA | 89 (50.0) | 65 (51.2) | - | 22 (47.8) | 27 (49.1) | 40 (51.9) | - |
| KRAS | n (%) | n (%) | 1 | n (%) | n (%) | n (%) | 0.839 |
| KRAS wt | 24 (13.5) | 17 (13.4) | - | 7 (15.2) | 8 (14.5) | 9 (11.7) | - |
| KRAS mut | 13 (7.3) | 9 (7.1) | - | 5 (10.9) | 4 (7.3) | 4 (5.2) | - |
| NA | 141 (79.2) | 101 (79.5) | - | 34 (73.9) | 43 (78.2) | 64 (83.1) | - |
| NRAS | n (%) | n (%) | 1 | n (%) | n (%) | n (%) | 0.553 |
| NRAS wt | 37 (20.8) | 26 (20.5) | - | 11 (23.9) | 12 (21.8) | 14 (18.2) | - |
| NRAS mut | 2 (1.1) | 1 (0.8) | - | 1 (2.2) | 1 (1.8) | 0 (0.0) | - |
| NA | 139 (78.1) | 100 (78.7) | - | 34 (73.9) | 42 (76.4) | 63 (81.8) | - |
CRC—colorectal cancer, TMS—tumour microbial subtypes, SD—standard deviation, NA—not available, pT—tumour pathologic stage, pTis—tumour in situ, pN—regional lymph nodes pathologic stage, M—synchronous distant metastasis, MSI—microsatellite instability MSS—microsatellite stable, wt—wild type, mut—mutation.